Therapeutic Outcome of Epstein-Barr Virus Positive T/NK Cell Lymphoma in the Upper Aerodigestive Tract.
10.3349/ymj.2002.43.2.175
- Author:
Jee Sook HAHN
1
;
Seung Tae LEE
;
Yoo Hong MIN
;
Yun Woong KO
;
Woo Ick YANG
;
Gwi Eon KIM
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. medi@yumc.yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
CD 56+;
T/NK cell lymphoma;
Epstein-Barr virus
- MeSH:
Adult;
Aged;
Digestive System Neoplasms/*therapy/virology;
Female;
Herpesvirus 4, Human/isolation & purification;
Human;
*Killer Cells, Natural;
Lymphoma/*therapy/virology;
Lymphoma, T-Cell/*therapy/virology;
Male;
Middle Age;
Respiratory Tract Neoplasms/*therapy/virology;
Treatment Outcome
- From:Yonsei Medical Journal
2002;43(2):175-182
- CountryRepublic of Korea
- Language:English
-
Abstract:
Expression of the natural killer (NK) cell antigen CD56 is uncommon in malignant lymphoma, but when it is, it is almost exclusively of the non-B cell lineage and show a preference for the nasal and nasopharyngeal region. T/NK cell lymphoma is known to be aggressive and refractory to treatment. It is highly associated with the Epstein-Barr Virus (EBV), but clinical investigations are rarely reported, that is until recently. We report here, on the clinical features and therapeutic outcomes of patients with T/NK cell lymphomas and its association with EBV. We reviewed fifty-four cases with peripheral T cell lymphomas in the upper aerodigestive tract between Jan. 1987 and Aug. 1998 from the Severance Hospital, Yonsei University College of Medicine. The diagnosis of T/NK cell lymphoma was made according to the expression of the NK cell markers, CD56 antigen and cytoplasmic CD3 epsilon, in tumor specimens, by immunohistochemistry. Epstein-Barr early region (EBER) RNA was detected using in situ hybridization on paraffin-embedded sections. Among the 54 cases with malignant lymphomas occurring in the upper aerodigestive tract, 20 had T/NK cell lymphoma (37%). The primary sites of T/NK cell lymphomas were the nasal cavity, 12 cases (60%), the tonsils, 4 cases (20%), the nasopharynx, 2 cases (10%), and the oropharynx, 2 case (10%). There were no differences between the features, at diagnosis or therapeutic modalities for patients with T/NK cell lymphoma and non-T/NK cell lymphoma. The complete remission rate of T/NK cell lymphomas was lower than non-T/NK cell lymphomas (65% vs 85%, p=0.02). The overall survival of T/NK cell lymphomas was 13 months (1-74 month), which was significantly lower than non-T/NK cell lymphomas [60.6% with a median follow up of 22 months (1-101 month, p=0.02)]. Disease free survival of T/NK cell lymphomas was 22 months (4-66 month), significantly lower than non-T/NK cell lymphomas [73.8% with a median follow up of 22 months (2-95 month), p=0.04]. The overall survival rates for T/NK cell lymphomas were significantly lower than for EBV positive non-T/NK cell lymphomas (p=0.018). EBER RNA was detected in the paraffin-embedded tissue sections of all T/NK cell lymphomas, compared to only 17.6% (6 of 34 cases) for non- T/NK cell lymphomas. In conclusion, as patients with T/NK cell lymphomas showed poor clinical outcomes, and a high association with EBV positivity, clinical trials with more investigational therapeutic strategies, and further research into the relationship of EBV infection with pathogenesis of T/NK cell lymphoma is warranted.
